Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948685 | 0.78 | AAK1 (0.33) | AAK1CA12CA1CA9 | |
| SCHEMBL9948908 | 0.77 | AAK1 (0.34) | AAK1 | |
| SCHEMBL323430 | 0.75 | AAK1 (0.38) | AAK1S1PR1S1PR3SMN1; SMN2HTT | |
| SCHEMBL1577309 | 0.73 | AAK1 (0.32) | AAK1S1PR1S1PR3 | |
| SCHEMBL1716656 | 0.73 | CA12 (0.33) | KMT2ACA12CA1CA9 | |
| SCHEMBL12145022 | 0.72 | AAK1 (0.52) | AAK1S1PR1S1PR3 | |
| SCHEMBL30012981 | 0.72 | AAK1 (0.38) | AAK1S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL27149274 | 0.72 | AAK1 (0.38) | AAK1S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL1404066 | 0.72 | AAK1 (0.42) | AAK1S1PR1S1PR3SMN1; SMN2HTT | |
| SCHEMBL1180451 | 0.70 | AAK1 (0.41) | AAK1S1PR1S1PR3SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087236-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | BACE1, BACE2, PSEN1 | AAK1 1462/4885S1PR1 1448/4885S1PR3 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.